Methods comprising apoptosis inhibitors for the generation of transgenic pigs

Stem Cell Clinic
Patient Application
3D Culture/Scaffold

Stem Cell Related Patent Number US5770429

Title:Transgenic non-human animals capable of producing heterologous antibodies
Inventors:Lonberg, Nils; Redwood City, CA, USA
Summary:This invention describes transgenic non-human animals which are capable of producing heterologous or chimeric antibodies, for purposes of binding a pre-determined human antigen with increased affinity. Disclosed are methods of producing such human sequence antibodies, as well as a monoclonal human immunoglobulin composition which is free of other human proteins, and which comprises a human sequence IgG having a binding constant of at least 2?109 M-1 for binding to a predetermined human antigen. Such an immunoglobulin consists of a somatically mutated human sequence light chain composed of a light chain variable region having a polypeptide sequence which is substantially identical to a polypeptide sequence encoded by a human VL gene segment and a human JL segment. Further polypeptide sequences of human heavy chain transgenes and light chain constant regions are also disclosed, as well as the gene segments encoding them, such that the human sequence heavy chain and human sequence light chain are separately encoded by a human heavy chain transgene and a human light chain transgene integrated into a mouse cell genome. Also provided are potential therapeutic uses of such methods in the treatment of genetic diseases associated with hematopoietic cells, such as sickle cell anaemia, among other disorders.
Abstract:The invention relates to transgenic non-human animals capable of producing heterologous antibodies and methods for producing human sequence antibodies which bind to human antigens with substantial affinity.
US Patent Website:Click Here for Full Text of Patent
Title Number:US5770429
Application Number:US1995000544404
Date Filed:10/10/1995
Date Published:23/06/1998
Assignee:GenPharm International, Inc., Palo Alto, CA, USA

Copyright © 2007 The Institute for Cellular Medicine  9/30/2022